Clinical Trials Sponsored by Shenzhen Geno-Immune Medical Institute

Total 145 results

Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/CD56 Bi-specific CAR-T Cell Therapy

Malignant Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

PSMA/CD70 Bi-specific CAR-T Cell Therapy

Cancer Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

T-Cell Acute Lymphoblastic Leukemia

China
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

B-Cell Acute Lymphoblastic Leukemia

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Multiple CAR-T Cell Therapy Targeting AML

Acute Myeloid Leukemia

China
Shenzhen Geno-Immune Medical Institute

Unknown

Gene Transfer for ADA-SCID Using an Improved Lentiviral Vector (TYF-ADA)

Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)

China
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral Gene Therapy for MLD

Metachromatic Leukodystrophy (MLD)

China
Shenzhen Geno-Immune Medical Institute

Unknown

Engineered Immune Effectors Against Cervical Cancer

Cervical Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells

Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Antigen-specific T Cells Against Lung Cancer

Lung Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Intervention of CAR-T Against Cervical Cancer

Cervical Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

B-cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Unknown

Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders

Tissue Damage | Immune Related Disorder

China
Shenzhen Geno-Immune Medical Institute

Unknown

Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector

Beta-Thalassemia

China
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/CD70 Bi-specific CAR-T Cell Therapy

Cancer Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/PSMA Bi-specific CAR-T Cell Therapy

Solid Tumor

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/22 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Sarcoma | Ewing Sarcoma | Osteoid Sarcoma

China
Shenzhen Geno-Immune Medical Institute

Enrolling by invitation

Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme

Glioblastoma Multiforme | Glioblastoma Multiforme of Brain

China
Shenzhen Geno-Immune Medical Institute

Unknown

Engineered Immune Effectors Against Ovarian Cancer

Ovarian Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Gene Transfer for SCID-X1 Using a Self-inactivating Lentiviral Vector （TYF-IL-2Rg）

SCID, X Linked

China
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral Gene Therapy for CGD

Chronic Granulomatous Disease

China
Shenzhen Geno-Immune Medical Institute

Unknown

HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV

Human Papilloma Virus

China
Shenzhen Geno-Immune Medical Institute

Unknown

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

B-cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Unknown

FANCA Gene Transfer for Fanconi Anemia Using a High-safety, High-efficiency, Self-inactivating Lentiviral Vector

Fanconi Anemia

China
Shenzhen Geno-Immune Medical Institute

Unknown

Immunotherapy Treating GI Cancer

Cancer

China
Shenzhen Geno-Immune Medical Institute

Withdrawn

Intervention of Engineered Immune Effector T Cells Against Lung Cancer

NSCLC | Lung Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Study on GD2 Positive Solid Tumors by 4SCAR-GD2

Solid Tumor

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells

Autoimmune Diseases

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/79b Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/70 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CAR-T Immunotherapy Targeting CD19- ALL

B-cell Leukemia

China
Shenzhen Geno-Immune Medical Institute

Unknown

Genetically Modified T Cells Against Ovarian Cancer

Ovarian Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Intervention of Bladder Cancer by CAR-T

Bladder Cancer | Urothelial Carcinoma Bladder

China
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral Gene Therapy for X-ALD

X-linked Adrenoleukodystrophy

China
Shenzhen Geno-Immune Medical Institute

Unknown

Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections

Tuberculosis | CMV Infection | EBV Infection | Adenovirus Infection | Fungus Infection | Pathogen Infection | BKV Infection

China
Shenzhen Geno-Immune Medical Institute

Unknown

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Multiple Myeloma

China
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral FIX Gene Therapy

Hemophilia B
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral FVIII Gene Therapy

Hemophilia A

China
Shenzhen Geno-Immune Medical Institute

Suspended

Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

Ovarian Cancer

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital

Recruiting

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Neuroblastoma

China
Zhujiang Hospital
Shenzhen Geno-Immune Medical Institute

Withdrawn

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

B-Cell Leukemia | B-Cell Lymphoma

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital; Shenzhen Hospital of Southern Medical University

Unknown

Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis

Cancer

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Second People's Hospital; Shenzhen Third People's Hospital

Recruiting

Safety and Immunity of Covid-19 aAPC Vaccine

Treat and Prevent Covid-19 Infection

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Second People's Hospital; Shenzhen Third People's Hospital

Recruiting

Immunity and Safety of Covid-19 Synthetic Minigene Vaccine

Pathogen Infection Covid-19 Infection

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital; Shenzhen Hospital of Southern Medical University

Unknown

Immune Modulatory DC Vaccine Against Brain Tumor

Diffuse Intrinsic Pontine Glioma or Glioblastoma

China
Shenzhen Geno-Immune Medical Institute
Sun Yat-sen University; Shenzhen Children's Hospital

Recruiting

Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276

Solid Tumor

China
The First People's Hospital of Yunnan
Shenzhen Geno-Immune Medical Institute

Unknown

A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia

B Acute Lymphoblastic Leukemia

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University

Recruiting

Universal CAR-T Cells Targeting Multiple Myeloma

Multiple Myeloma in Remission

China

Clinical Trials Sponsored by Shenzhen Geno-Immune Medical Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations